Tumor specific vaccination therapy for advanced/recurrent cervical cancer using HLA-A*2402 restricted Specific Epitope Peptides Cocktail derived from Tumor genom/Tumor related Angiogenetic factors genom

Tumor specific vaccination therapy for advanced/recurrent cervical cancer using HLA-A*2402 restricted Specific Epitope Peptides Cocktail derived from Tumor genom/Tumor related Angiogenetic factors genom - Therapeutic vaccination therapy for cervical cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003902

Enrollment

Registered

2010-07-11

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced/recurrent cervical cancer with the conditions of unremoval by surgery, or refractory, chemo-resistant disease.

Interventions

peptides Vaccine

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.Unresectable advanced/recurrent cervical cancer(CC) patient with prior chemotherapy/chemo-radiotherapy including standard chemotherapy for cervical cancer, and who are identified as chemoresistent and/or further chemotherapy would not continue due to their adverse events (AEs) is eligible. 2. Performance Status (PS) 0-2 3. Age:20-80 years old, in principle 4. patients with measurable/detectable disease using CT/MRI would be favorable(The existence of targeted lesion using RECIST version 1.01 would be more favorble) 5.The treatment interval from the latest prior therapy must be more than 28days. 6. Prospective survival would be 3months or over. 7. Organ functions (stated bellow) must be reserved: bone marrow function (WBC conts:2000-1,0000/mm3, Platelet: over 50,000/mm3,GOT(AST) and GPT(ALT): less than </=150IU/L, T-Bil:</=3.0mg/dL, Crn</=3.0mg/dL 8.HLA-A2402 is positive 9. written informed consent is necessary

Exclusion criteria

Exclusion criteria: 1. pregnant women 2. breast feeding mothor(stop brest feeding) 3.women who are willing to be pregnant(must perform contraception) 4.complication of uncontrolable infection 5.Usage of continual systemic steroid and immuno-suppressant is prohibited during treatment. 6. Who are recognized ineligible by the resiponsible investigator or investigators

Design outcomes

Primary

Measure	Time frame
Safety and Overall survival	—

Secondary

Measure	Time frame
time to progression, evaluation of QOL, immunological evaluation, response rate	—

Countries

Japan

Contacts

Public ContactSatoshi Takeuchi

Iwate Medical University School of Medicine Department of obstetrics and gynecology Gynecologic Oncology

s-take-imugo@zeus.eonet.ne.jp81-19-651-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026